Home / Business and Economy / ARK Divests Figma, Doubles Down on Biotech and AI
ARK Divests Figma, Doubles Down on Biotech and AI
26 Jul
Summary
- ARK sold 718,303 Figma shares for $14,366,060.
- ARK purchased 361,253 Scribe Therapeutics shares for $5,418,795.
- ARK acquired shares in AI companies Kodiak AI and Pony AI.
On Friday, July 24th, 2026, Cathie Wood's ARK ETF executed notable trades, indicating a strategic pivot. The firm significantly reduced its stake in design software company Figma Inc (FIG), selling 718,303 shares across its ARKK and ARKW ETFs for a total of $14,366,060. This move aligns with recent divestments from the company.
Conversely, ARK demonstrated strong confidence in the biotechnology sector by acquiring 361,253 shares of Scribe Therapeutics Inc (SCTX) through its ARKG ETF, amounting to $5,418,795. This purchase highlights ARK's increasing focus on advanced genome editing technologies.
Further diversifying its portfolio, ARK also purchased shares in artificial intelligence companies, adding 47,500 shares of Kodiak AI Inc (KDK) and 40,404 shares of Pony AI Inc (PONY) via its ARKQ ETF. These acquisitions underscore ARK's commitment to AI-driven innovations.
In other notable transactions, ARK sold 758,353 shares of ATAI Beckley Inc (ATAI) for $5,437,391 and increased its stake in X-Energy Inc (XE) by purchasing 120,704 shares, reflecting a dynamic approach to sector investment.
